In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy’s $500 Million GMP Settlement Would Be Second Most Expensive For Rx Manufacturing Violations

Executive Summary

Ranbaxy Laboratories said it has signed a consent decree with FDA and set aside $500 million to settle a related Department of Justice investigation involving GMP violations and data integrity issues at its Indian facilities.

You may also be interested in...



FDA Investigators Want Top Management Involved In Manufacturing Inspections

FDA’s expectation is that the most responsible individual at manufacturing sites be involved in inspections. The agency is increasingly talking about its “responsible corporate official” or Park Doctrine powers to hold top officials responsible for manufacturing issues and problems.

Germany Blocks Cephalosporin Exports From Ranbaxy’s Dewas Unit

Ranbaxy is back in the news for GMP violations at its Dewas unit in India. Based on an inspection in June, this time Germany’s drug regulator has raised the red flag, citing deficiencies in design and clean room operations, among others. For its part, Ranbaxy clarified that it had decided to discontinue making injectable cephalosporins well before the joint inspection and that all its other facilities were cleared post the inspection.

How Sun Pharma Clinched Ranbaxy – The Inside Story

Sun Pharma’s Dilip Shanghvi bought out Ranbaxy to push ahead in the fast-evolving global generics industry. In contrast to wide speculation that the Ranbaxy deal was inked over a short time, bankers who spoke divulged a well-planned and studied move that began as early as in 2012 and culminated into the final agreement now.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS054073

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel